Delgocitinib ointment 0.5% is the world's first topical Janus kinase inhibitor product and was approved for treatment of atopic dermatitis (AD) in Japan. Although topical corticosteroids (TCSs) have been the mainstay of pharmacotherapy in AD over the past decades, long-term use of TCSs causes skin atrophy and alteration of the epidermal tight junction (TJ) leading to epidermal barrier dysfunction. In this study, delgocitinib ointment 0.5% or representative TCSs of different potencies were applied dermally once daily to the ear pinna of normal ICR mice for 14 days, and ear pinna thickness, histopathology, and immunohistochemistry for epidermal TJ proteins claudin-1 and -4 were evaluated. All the TCSs caused decreases in ear pinna thickness with epidermal thinning, sebaceous gland atrophy, and atrophy/decreased number of the subcutaneous adipocytes and decreased immunohistochemical staining intensity for epidermal claudins. In contrast, delgocitinib ointment 0.5% did not cause any of those changes. In conclusion, once daily topical delgocitinib ointment 0.5% for 14 days did not cause skin atrophy or decreased immunohistochemical staining of epidermal claudins, which are common safety concerns associated with TCSs. These characteristics suggest that delgocitinib ointment 0.5% has an improved safety profile over currently available TCS therapies particular for the long-term AD treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/0192623320970896 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
English version of clinical practice guidelines for the management of atopic dermatitis 2024.
J Dermatol
December 2024
Medical Informatics and Management, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
This is the English version of the 2024 clinical practice guidelines for the management of atopic dermatitis (AD). AD is a disease characterized by relapsing eczema with pruritus as a primary lesion. A crucial aspect of AD treatment is the prompt induction of remission via the suppression of existing skin inflammation and pruritus.
View Article and Find Full Text PDFPost-hoc safety/efficacy analyses from pediatric delgocitinib atopic dermatitis trials.
Pediatr Int
October 2024
Department of Dermatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Article Synopsis
- Delgocitinib ointment is primarily recommended at a 0.25% concentration for children, but a 0.5% formulation may be considered based on symptom severity, with unclear safety data when used with other treatments.
- A post-hoc analysis compared the efficacy and safety of 0.25% and 0.5% formulations over up to 4 and 56 weeks in pediatric patients, focusing on combinations with topical corticosteroids and tacrolimus.
- Results showed the 0.5% formulation was more effective for mild cases, while both dosages were well-tolerated with no significant safety differences, even when used alongside other medications.
Topical JAK inhibition ameliorates EGFR inhibitor-induced rash in rodents and humans.
Sci Transl Med
June 2024
School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200240, China.
Article Synopsis
- Epidermal growth factor receptor inhibitors (EGFRis) can treat various cancers, but they often cause severe skin rashes that negatively impact patients' quality of life.
- Research shows that the activation of keratinocytes, along with S100A9 protein induction, happens early in the development of these rashes, which leads to an immune response that exacerbates the skin condition.
- Treatment with topical JAK inhibitors has been effective in reducing the severity of the rash in animal models and showed promising results in a pilot clinical trial, indicating potential management strategies for this side effect.
Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis.
Front Pharmacol
April 2024
Departments of Nuclear Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Article Synopsis
- - We conducted a Bayesian network meta-analysis on 13 trials with 3,613 patients to evaluate the efficacy and safety of new JAK inhibitors for treating moderate-to-severe alopecia areata, finding that brepocitinib 30mg was the most effective in improving SALT scores.
- - Deuruxolitinib 12mg showed strong effectiveness for severe cases, but it also had a higher likelihood of causing adverse events, while ritlecitinib 50mg appeared to balance safety and efficacy better among high-dose oral options.
- - The study highlights a need for more extensive head-to-head trials over longer periods to validate these findings and further assess the long-term safety of these treatments for alopecia
Alopecia areata in a patient with cytotoxic T lymphocyte antigen-4 haploinsufficiency successfully treated with topical delgocitinib ointment.
J Eur Acad Dermatol Venereol
January 2024
Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!